Wide Ranks

CHRS

Coherus BioSciences, Inc.

1.26

Top Statistics
Market Cap 145 M Forward PE -623.76 Revenue Growth -5.10 %
Current Ratio 1.25 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -0.15 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.71 Enterprise / Revenue 1.04 Price To Sales Trailing12 Months 0.4770
Profitability
Profit Margins -0.15 % Operating Margins -9.02 %
Balance Sheet
Total Cash 97 M Total Cash Per Share 0.8480 Total Debt 269 M
Total Debt To Equity Current Ratio 1.25 Book Value Per Share -0.7640
All Measures
Short Ratio 1234.00 % Message Board Id finmb_206928583 Shares Short Prior Month 29 M
City Redwood City Uuid c75daf8f-3c65-3d43-b809-ee892c342721 Previous Close 1.28
First Trade Date Epoch Utc 1 B Book Value -0.7640 Beta 0.6930
Total Debt 269 M Volume 3 M Fifty Two Week Low 0.6600
Total Cash Per Share 0.8480 Total Revenue 304 M Shares Short Previous Month Date 1 B
Target Median Price 7.00 Audit Risk 8 Max Age 86400
Recommendation Mean 1.75 Sand P52 Week Change 0.3133 Operating Margins -9.02 %
Target Mean Price 6.50 Net Income To Common -450000 Short Percent Of Float 0.3346
Implied Shares Outstanding 115 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 4 M Average Volume10days 4 M Total Cash 97 M
Next Fiscal Year End 1 B Revenue Per Share 2.68 Held Percent Insiders 0.0139
Ebitda Margins -38.42 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 1.28
Target Low Price 1.50 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.9220
Open 1.28 Free Cashflow 42 M State CA
Dividend Yield 0.00 % Return On Assets -0.1403 Time Zone Short Name EST
Board Risk 6 Trailing Eps -0.0900 Day Low 1.23
Address1 333 Twin Dolphin Drive Shares Outstanding 115 M Compensation Risk 8
Price Hint 4 Target High Price 12.00 Website https://www.coherus.com
52 Week Change -0.4085 Average Volume 2 M Forward Eps -0.2700
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 100.30 %
Is_sp_500 False Regular Market Day High 1.35 Profit Margins -0.15 %
Fifty Two Week High 3.70 Day High 1.35 Shares Short 33 M
Regular Market Open 1.28 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1.04 Revenue Growth -5.10 % Shares Percent Shares Out 0.2868
Operating Cashflow -61985000 Currency USD Time Zone Full Name America/New_York
Market Cap 145 M Is_nasdaq_100 False Zip 94065
Quote Type EQUITY Industry Biotechnology Long Name Coherus BioSciences, Inc.
Overall Risk 7 Regular Market Day Low 1.23 Held Percent Institutions 0.7009
Current Price 1.26 Address2 Suite 600 Enterprise To Ebitda -2.71
Financial Currency USD Current Ratio 1.25 Gross Margins 44.71 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 103 M Two Hundred Day Average 1.63 Governance Epoch Date 1 B
Enterprise Value 317 M Price To Sales Trailing12 Months 0.4770 Forward PE -623.76
Regular Market Volume 3 M Ebitda -116920000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States.

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.

In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors.

Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis.

It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.

4 Limited.

The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.

Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.